^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Marginal Zone Lymphoma
    Drug:Imbruvica (ibrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    01/20/2021
    Excerpt:
    Marginal Zone Lymphoma: SECOND-LINE AND SUBSEQUENT THERAPY FOR ELDERLY OR INFIRM…Preferred Regimens…Ibrutinib